SMS Lifesciences India Limited
NSE: SMSLIFE BSE: SMSLIFE
Prev Close
1352.9
Open Price
1384
Volume
4
Today Low / High
1310.1 / 1384
52 WK Low / High
959.8 / 1680
Range
1,254 - 1,386
Prev Close
1338.8
Open Price
1405.7
Volume
3
Today Low / High
1399.9 / 1405.7
52 WK Low / High
956.05 / 1680
Range
1,330 - 1,470
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1320 (target range: 1,254 - 1,386), reflecting a change of -32.9 (-2.43181%). On the BSE, it is listed at 1399.9 (target range: 1,330 - 1,470), showing a change of 61.1 (4.56379%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
SMS Lifesciences India Limited Graph
SMS Lifesciences India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for SMS Lifesciences India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,320.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,399.90 | 1,413.90 | 1,272.51 - 1,555.29 |
| 1,427.90 | 1,142.32 - 1,713.48 | ||
| 1,441.90 | 1,009.33 - 1,874.47 | ||
| Bearish Scenario | 1,399.90 | 1,385.90 | 1,247.31 - 1,524.49 |
| 1,371.90 | 1,097.52 - 1,646.28 | ||
| 1,357.90 | 950.53 - 1,765.27 |
Overview of SMS Lifesciences India Limited
ISIN
INE320X01016
Industry
Biotechnology
Vol.Avg
4,383
Market Cap
4,111,670,320
Last Dividend
1.5
Official Website
IPO Date
2017-08-18
DCF Diff
1,913.80
DCF
-868
Financial Ratios Every Investor Needs
Stock Dividend of SMSLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-24 | September 24, 25 | 1.5 | 1.5 | 2025-09-24 | 2025-10-30 | |
| 2024-09-23 | September 23, 24 | 1.5 | 1.5 | 2024-09-23 | 2024-10-30 | |
| 2023-09-22 | September 22, 23 | 1.5 | 1.5 | 2023-09-22 | 2023-10-29 | |
| 2022-09-22 | September 22, 22 | 1.5 | 1.5 | 2022-09-23 | 2022-10-30 | |
| 2021-09-20 | September 20, 21 | 1.5 | 1.5 | 2021-09-21 | 2021-10-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 344.72 Cr | 294.15 Cr | 50.58 Cr | 0.1467 | 5.39 Cr | 59.60 Cr | 30.04 Cr | 20.11 Cr | 66.52 | 49.90 Cr | 0.0583 |
| 2024-03-31 | 305.96 Cr | 209.71 Cr | 96.24 Cr | 0.3146 | 4.55 Cr | 3.39 Cr | 35.95 Cr | 9.09 Cr | 30.08 | 34.94 Cr | 0.0297 |
| 2023-03-31 | 315.56 Cr | 228.00 Cr | 87.56 Cr | 0.2775 | 8.02 Cr | 3.24 Cr | 17.34 Cr | 11.46 Cr | 37.92 | 34.18 Cr | 0.0363 |
| 2022-03-31 | 347.30 Cr | 259.76 Cr | 87.54 Cr | 0.2521 | 2.87 Cr | 2.69 Cr | 22.54 Cr | 25.32 Cr | 83.76 | 48.91 Cr | 0.0729 |
| 2021-03-31 | 265.59 Cr | 187.25 Cr | 70.21 Cr | 0.2644 | 1.95 Cr | 3.11 Cr | 24.69 Cr | 13.56 Cr | 44.84 | 31.96 Cr | 0.0510 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.51 Cr | 389.99 Cr | 177.94 Cr | 196.5603 Cr | 86.41 Cr | 84.90 Cr | 67.40 Cr | 232.20 Cr | 0.00 Cr | 0.00 Cr | 3.29 Cr | 142.0676 Cr |
| 2024-03-31 | 0.57 Cr | 390.52 Cr | 196.88 Cr | 176.8142 Cr | 100.72 Cr | 100.15 Cr | 81.21 Cr | 232.02 Cr | 8.71 Cr | 2.39 Cr | 0.04 Cr | 145.3683 Cr |
| 2023-03-31 | 0.15 Cr | 394.89 Cr | 206.67 Cr | 164.0280 Cr | 100.49 Cr | 86.85 Cr | 86.23 Cr | 140.39 Cr | 9.74 Cr | 3.62 Cr | 3.08 Cr | 133.5643 Cr |
| 2022-03-31 | 0.99 Cr | 356.75 Cr | 191.82 Cr | 152.2323 Cr | 79.60 Cr | 78.61 Cr | 84.81 Cr | 193.09 Cr | 4.76 Cr | 43.84 Cr | 2.75 Cr | 135.4405 Cr |
| 2021-03-31 | 8.54 Cr | 302.30 Cr | 173.08 Cr | 129.2163 Cr | 64.69 Cr | 56.15 Cr | 61.63 Cr | 151.00 Cr | 15.42 Cr | 0.00 Cr | 0.04 Cr | 113.5996 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.8096 Cr | -15.0607 Cr | -14.8154 Cr | 14.4610 Cr | 0.0156 Cr | 1.5081 Cr | -15.3486 Cr | 20.1090 Cr | -13.7433 Cr | -0.4535 Cr | 13.8126 Cr |
| 2024-03-31 | 24.3055 Cr | -18.4503 Cr | -6.5635 Cr | 3.4378 Cr | -0.7083 Cr | 0.5695 Cr | -20.8677 Cr | 9.0928 Cr | -0.9758 Cr | -0.4535 Cr | 5.0245 Cr |
| 2023-03-31 | 14.6950 Cr | -31.2916 Cr | 16.8884 Cr | -0.0003 Cr | 0.2918 Cr | 0.0000 Cr | -0.0005 Cr | 0.0001 Cr | 21.3465 Cr | -0.4535 Cr | 0.0000 Cr |
| 2022-03-31 | -11.2409 Cr | -7.1428 Cr | 10.8335 Cr | -62.3940 Cr | -7.5503 Cr | 0.9860 Cr | -51.1531 Cr | 20.0388 Cr | 13.0419 Cr | -0.4535 Cr | -24.1950 Cr |
| 2021-03-31 | 35.1698 Cr | -26.2348 Cr | -2.5465 Cr | -0.3866 Cr | 6.3885 Cr | 8.5363 Cr | -35.5564 Cr | 19.5675 Cr | 0.5091 Cr | 0.0000 Cr | 2.6665 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 81.37 Cr | 68.45 Cr | 12.91 Cr | 0.1587 | 9.68 Cr | 6.10 Cr | 20.19 | 13.99 Cr | 0.0750 |
| 2025-06-30 | 82.50 Cr | 51.64 Cr | 30.86 Cr | 0.3740 | 7.89 Cr | 4.16 Cr | 13.75 | 12.71 Cr | 0.0504 |
| 2025-03-31 | 89.11 Cr | 76.59 Cr | 12.53 Cr | 0.1406 | 3.62 Cr | 2.97 Cr | 9.83 | 9.76 Cr | 0.0334 |
| 2024-12-31 | 84.60 Cr | 53.17 Cr | 31.43 Cr | 0.3715 | 9.00 Cr | 5.47 Cr | 18.08 | 12.81 Cr | 0.0646 |
| 2024-09-30 | 78.46 Cr | 50.47 Cr | 27.99 Cr | 0.3568 | 4.80 Cr | 4.67 Cr | 15.46 | 10.60 Cr | 0.0596 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.54 Cr | 1.03 Cr | 1.57 Cr | 61.04 Cr | 71.04 Cr | 148.68 Cr | 234.81 Cr | 393.89 Cr | 171.41 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -212.05 Cr |
| 2025-03-31 | 1.51 Cr | 0.00 Cr | 1.51 Cr | 68.79 Cr | 67.40 Cr | 150.57 Cr | 232.20 Cr | 389.99 Cr | 177.94 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.19 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -203.32 Cr |
| 2024-09-30 | 0.27 Cr | 0.92 Cr | 1.19 Cr | 71.22 Cr | 71.09 Cr | 154.70 Cr | 230.03 Cr | 391.40 Cr | 188.09 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 4.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 2.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 5.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 4.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 7.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹384.30 | ₹513,069,704,494.00 | ₹1,581,157.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹642.55 | ₹360,862,538,270.00 | ₹177,922.00 |
| Syngene International Limited | SYNGENE | ₹655.85 | ₹263,465,378,262.00 | ₹235,392.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹180.08 | ₹238,257,917,966.00 | ₹2,721,264.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,798.90 | ₹206,127,201,150.00 | ₹87,776.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,354.70 | ₹141,723,571,559.00 | ₹52,219.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹744.30 | ₹117,579,169,926.00 | ₹284,099.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹525.50 | ₹91,156,080,838.00 | ₹237,123.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹751.50 | ₹60,482,824,200.00 | ₹132,795.00 |
| Zota Health Care Limited | ZOTA | ₹1,509.70 | ₹45,793,209,254.00 | ₹30,820.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹256.53 | ₹40,219,567,360.00 | ₹228,730.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1957
Gender: male
Year Born: 1960
Gender: male
Year Born: 1983
Gender: male
Year Born:
Gender: male
Year Born:
Gender: female
Year Born: 1987
FAQs about SMS Lifesciences India Limited
The CEO is Talluri Veera Venkata Satyanarayana Murthy.
The current price is ₹1,360.00.
The range is ₹959.8-1680.
The market capitalization is ₹411.17 crores.
The dividend yield is 0.11%.
The P/E ratio is 21.99.
The company operates in the Healthcare sector.
Overview of SMS Lifesciences India Limited (ISIN: INE320X01016) is a leading Biotechnology in India. With a market capitalization of ₹411.17 crores and an average daily volume of 4,383 shares, it operates in the Biotechnology. The company last declared a dividend of ₹1.5.